Novo Nordisk to share new trial data at EASD's 60th annual meeting
Bagsværd, Denmark, 6 September 2024 – Novo Nordisk announced the presentation of 21 abstracts at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD), scheduled from 9 to 13 September 2024 in Madrid, Spain. The presentations will consist of seven oral and 14 short oral presentations, along with data revealed at scientific symposia. Key studies to be presented include the COMBINE clinical program examining IcoSema, a combination of once-weekly basal insulin icodec and once-weekly semaglutide for type 2 diabetes, the FLOW trial assessing semaglutide 1.0 mg's impact on kidney outcomes in type 2 diabetes patients with chronic kidney disease, and amylin treatment for metabolic diseases.
Martin Holst Lange, executive vice president and head of Development at Novo Nordisk, emphasized the critical need for comprehensive treatment options for cardiometabolic conditions like diabetes, obesity, cardiovascular, and kidney diseases. "Cardiometabolic conditions like diabetes, obesity, cardiovascular and kidney disease, all result from closely interlinked underlying risk factors and are among the most significant health challenges society faces today. Tailored treatment options that aim to holistically address these conditions are therefore needed," Lange stated. He highlighted Novo Nordisk's focus on advancing treatments to assist more patients, showcasing new data from their extensive diabetes, obesity, cardiovascular, and renal research pipeline.
Presentations at the EASD meeting will cover various topics, including:
- Diabetes Treatments:
- Awiqli®: This is a novel once-weekly basal insulin analogue designed to meet basal insulin needs with a single injection per week.
- Ozempic®: A once-weekly semaglutide 1.0 mg for adults with insufficiently controlled type 2 diabetes, used as an adjunct to diet and exercise or in combination with other diabetes medications.
- Obesity Treatments:
- Wegovy®: A semaglutide 2.4 mg injection for weight management in adults and adolescents, used alongside a reduced-calorie diet and physical activity.
- Saxenda®: A liraglutide 3.0 mg injection for weight management in adults and adolescents, also used with diet and exercise.
Additionally, Novo Nordisk will present insights into their digital health solutions and other research initiatives. These presentations will offer preliminary data, and final published manuscripts may contain updates.
Novo Nordisk continues to be a significant player in global healthcare, focusing on serious chronic diseases, primarily diabetes. Founded in 1923 and headquartered in Denmark, the company employs approximately 69,000 people across 80 countries and markets its products in around 170 countries. Their mission is driven by scientific innovation, expanded access to medicines, and efforts to prevent and ultimately cure diseases.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
